Announcement PDF ASX Announcement Change of Company Address Melbourne, Australia; 23 October 2026: Starpharma (ASX: SPL, US OTC: SPHRY) today advises that effective from Monday 26 October 2026, its registered office, principal place of business, and postal addresses will change as follows: To Suite 3.02, Level 3, 40 River Boulevard Richmond, Victoria, 3121 From 4-6 Southampton Crescent Abbotsford, Victoria, 3067 Starpharma’s phone number will remain the same: + 61 3 8532 2700. The address change also applies to Starpharma Holdings Limited’s Australian subsidiary, Starpharma Pty Ltd. About Starpharma Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—includingtheir size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications. Starpharma’s portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.